ClinicalTrials.gg
WithdrawnNCT00380835Updated Sep 23, 2008

Study of Amrubicin With or Without Herceptin in Patients With Metastatic Breast Cancer

A Phase 2 interventional study of Amrubicin in Metastatic Breast Cancer, sponsored by Celgene Corporation. Withdrawn at 28 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2008-09-23.

Sponsored by Celgene Corporation (part of Bristol-Myers Squibb) · Phase 2, Interventional, and Treatment

Why this study was withdrawn
Study Never Initiated

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
66
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 44 studies in Breast Neoplasms by Bristol-Myers Squibb — 4 open to participants now, 4 under way, 1 of them phase 3. Breast Neoplasms · Bristol-Myers Squibb.

Planned enrollment
22nd of 40
66 · median 73
Phase 2
23 of 44
none open now
Registered
12th of 44
by date

Among the 44 studies in Breast Neoplasms by Bristol-Myers Squibb, this one is the 22nd largest by planned enrollment of the 40 interventional ones that give a count, is one of 23 in phase 2, and was the 12th registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,320 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

4 of the 44 studies in Breast Neoplasms by Bristol-Myers Squibb are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Who these studies take

Of the 2,399 Breast Neoplasms studies recruiting now, 1,570 (65%) set no upper age limit and 592 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 44 studies in Breast Neoplasms by Bristol-Myers Squibb, or all of them as a file.
02

Study summary

The purpose of the study is to evaluate the incidence of cardiac toxicity of amrubicin when administered to patients with metastatic breast cancer.

03

Conditions studied

  • Metastatic Breast Cancer

Browse trials for

Keywords

  • metastatic breast cancer
  • amrubicin
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Histological or cytological diagnosis of breast cancer.
  • or recurrent disease, either + (FISH+ or 3+ IHC) or HER2-.
  • Maximal dose of prior adjuvant anthracycline: 300 mg/meters squared doxorubicin or equivalent. Relapse greater than one year after trastuzumab adjuvantly; two years following anthracycline therapy (without trastuzumab).
  • One prior chemotherapy for metastatic breast cancer allowed (may include trastuzumab for HER2+ patients), but no prior Doxil, adriamycin or epirubicin for metastatic breast cancer.
  • At least 18 years of age.
  • Performance Status of 0, 1, or 2.
  • Adequate organ function including the following:

    • Adequate bone marrow reserve.
    • Cardiac: (LVEF) greater than or equal to 55% by MUGA.
  • Negative serum pregnancy test at the time of enrollment for women of .
  • Ability to understand the requirements of the study, provide written and authorization of use and disclosure of protected health information, and agree to abide by the study restrictions and to return for the required assessments.

Exclusion criteria

Exclusion Criteria:

  • Pregnant or nursing women.
  • Concurrent anticancer therapy.
  • Participation in any drug study within 28 days prior to study entry.
  • Concurrent severe or uncontrolled medical disease (i.e., active systemic infection, diabetes, uncontrolled hypertension, coronary artery disease, congestive heart failure, severe arrhythmia) that, in the opinion of the Investigator, would compromise the safety of the patient or compromise the ability of the patient to complete the study.
  • Symptomatic central nervous system . Patients with asymptomatic are allowed. The patient must be stable after radiotherapy for greater than or equal to 2 weeks and off for greater than or equal to 1 week.
  • History of interstitial lung disease or pulmonary fibrosis.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
66 participants (estimated)

Interventions

06

What researchers measure

Primary outcomes

  1. Incidence of cardiac toxicity

Secondary outcomes

  1. Objective tumor response rate according to RECIST criteria measured every 2 cycles (every 6 weeks)

  2. Duration of overall response

  3. Time to tumor progression

  4. Progression free survival

  5. Toxicity profile

07

Study locations

28 sites
  • New Milford, Connecticut 06776, United States
  • Sharon, Connecticut 06069, United States
  • Torrington, Connecticut 06790, United States
  • Burnsville, Minnesota 55337, United States
  • Edina, Minnesota 55435-2150, United States
  • Maplewood, Minnesota 55109, United States
  • Minneapolis, Minnesota 55404, United States
  • St. Paul, Minnesota 55102-2389, United States
  • Woodbury, Minnesota 55125, United States
  • Columbia, Missouri 65201, United States
  • Albany, New York 12208, United States
  • Amsterdam, New York 12010, United States
  • Hudson, New York 12534, United States
  • Latham, New York 12110-0610, United States
  • Rexford, New York 12148, United States
  • Schenectady, New York 12308, United States
  • Troy, New York 12180, United States
  • Asheville, North Carolina 28803, United States
  • Dallas, Texas 75230-2510, United States
  • Dallas, Texas 75231-4400, United States
  • Dallas, Texas 75246, United States
  • El Paso, Texas 79902, United States
  • El Paso, Texas 79915, United States
  • Houston, Texas 77024, United States
  • Midland, Texas 79701-5946, United States
  • Odessa, Texas 79761, United States
  • Plano, Texas 75075-7787, United States
  • Tyler, Texas 75702, United States
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 23, 2008, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00380835
First posted
Sep 27, 2006
Completion
Dec 2007
Last update
Sep 23, 2008

Study contacts

Richard S Ungerleider, MD
study director · Theradex
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Sep 2008. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Amrubicin

Start the discussion